SS-31 Peptide: Targeting the Powerhouse of the Cell

SS-31, also known as elamipretide or Bendavia, is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) developed by Dr. Hazel Szeto at Weill Cornell Medicine. It belongs to the Szeto-Schiller (SS) peptide family — a class of cell-permeable, mitochondria-targeted peptides that concentrate in the inner mitochondrial membrane (IMM) with remarkable selectivity.

What makes SS-31 extraordinary is its targeting mechanism. Unlike most drugs that must navigate multiple cellular compartments to reach their target, SS-31 exploits an electrochemical gradient to concentrate 5,000-fold within the IMM relative to extracellular concentrations. This concentration occurs within minutes of administration and is independent of mitochondrial membrane potential — meaning SS-31 reaches even dysfunctional mitochondria that other mitochondria-targeted agents cannot access.

At the molecular level, SS-31 binds to cardiolipin — a phospholipid unique to the IMM that is essential for electron transport chain (ETC) function. Cardiolipin anchors cytochrome c to the IMM and maintains the structural integrity of ETC complexes I, III, IV, and V. When cardiolipin becomes oxidized (a hallmark of aging and disease), ETC efficiency collapses, ROS production increases, and the cell enters a vicious cycle of mitochondrial decline. SS-31 stabilizes cardiolipin-cytochrome c interactions, preventing cytochrome c peroxidase activity and restoring efficient electron transport. For foundational peptide science, see our comprehensive peptide guide.

Mitochondrial dysfunction is increasingly recognized as a central driver of aging and age-related disease. Understanding the scope of this problem contextualizes why SS-31 has generated significant research interest:

The Scale of Mitochondrial Involvement: Human cells contain 1,000–2,000 mitochondria, collectively generating approximately 90% of cellular ATP through oxidative phosphorylation. Mitochondria also regulate calcium homeostasis, apoptosis (programmed cell death), and cellular redox balance. When mitochondrial function declines, every energy-dependent cellular process is affected — from muscle contraction and neural signaling to protein synthesis and DNA repair.

Age-Related Decline: Mitochondrial function decreases approximately 10% per decade after age 30. By age 70, ATP production capacity may be reduced by 40–50% compared to young adults. This decline results from accumulated oxidative damage to mitochondrial DNA (which lacks the robust repair mechanisms of nuclear DNA), cardiolipin peroxidation, and declining mitophagy (the process of recycling damaged mitochondria).

Disease Associations: Mitochondrial dysfunction is documented in heart failure (where cardiac cells are the most mitochondria-dense in the body), neurodegenerative diseases (Alzheimer's, Parkinson's), kidney disease, skeletal muscle wasting (sarcopenia), and metabolic syndrome. The mitochondrial theory of aging, first proposed by Denham Harman in 1972, posits that cumulative oxidative damage to mitochondria is a primary driver of the aging process itself.

The Treatment Gap: Prior to SS-31, no pharmacological agent specifically targeted the inner mitochondrial membrane. Antioxidants like CoQ10 and vitamin E reduce systemic oxidative stress but do not concentrate in mitochondria sufficiently to address localized cardiolipin oxidation. MitoQ (a mitochondria-targeted CoQ10 derivative) reaches the mitochondrial matrix but does not directly stabilize cardiolipin-cytochrome c interactions. SS-31 fills this therapeutic gap with precision that no prior compound has achieved.

SS-31 has been studied in over 200 preclinical studies and multiple clinical trials. The documented ss-31 peptide benefits span multiple organ systems:

Cardiac Function: In a phase 2 clinical trial (EMBRACE STEMI) involving 297 patients with acute ST-elevation myocardial infarction, SS-31 (elamipretide) administered during reperfusion reduced infarct size by 13% compared to placebo. In heart failure models, SS-31 improved left ventricular ejection fraction by 15–20%, reduced cardiac fibrosis, and restored mitochondrial cristae structure. A 2020 study in Circulation Research showed SS-31 normalized cardiac energetics in aged mice, restoring diastolic function to levels seen in young animals.

Skeletal Muscle: Age-related muscle loss (sarcopenia) is driven partly by mitochondrial dysfunction in myofibers. SS-31 treatment in aged mice restored muscle mitochondrial content, improved exercise tolerance by 30%, and reduced the oxidative stress markers associated with muscle aging. A 2018 study in Aging Cell by Siegel et al. demonstrated that just 8 weeks of SS-31 treatment reversed age-related declines in skeletal muscle mitochondrial function, increasing ATP synthesis capacity by 30%.

Kidney Protection: SS-31 showed renoprotective effects in multiple models of acute kidney injury (AKI) and chronic kidney disease (CKD). In ischemia-reperfusion AKI models, SS-31 reduced tubular necrosis by 60% and preserved mitochondrial membrane potential. The REPAIR trial (phase 2) evaluated elamipretide in patients with atherosclerotic renal artery stenosis, demonstrating improved renal cortical blood flow and restored mitochondrial function.

Ophthalmic Applications: The ReCLAIM trials evaluated elamipretide for age-related macular degeneration (AMD). ReCLAIM-2, a phase 2 trial in 180 patients with dry AMD, showed improvements in low-luminance visual acuity and reduction in drusen volume at 48 weeks. These results are particularly significant because no approved treatments exist for dry AMD. Explore more anti-aging peptide research in our peptide therapy guide.

Neurological Effects: Preclinical studies demonstrate SS-31 improves mitochondrial function in neurons, reduces oxidative stress in the hippocampus, and improves cognitive function in aged animal models. Research published in Neurobiology of Aging showed SS-31 reversed age-related synaptic loss and restored long-term potentiation — the cellular mechanism underlying memory formation.

SS-31's mechanism is elegantly simple yet profoundly effective, targeting the fundamental biochemistry of mitochondrial energy production:

Cardiolipin Stabilization: SS-31 binds to cardiolipin through electrostatic interactions between its cationic residues (Arg and Lys) and cardiolipin's anionic phosphate groups, plus hydrophobic interactions between its aromatic residues (Tyr and Phe) and cardiolipin's acyl chains. This binding prevents cardiolipin peroxidation and maintains the phospholipid's ability to anchor cytochrome c to the IMM in its electron carrier conformation.

Cytochrome c Function Restoration: In healthy mitochondria, cytochrome c shuttles electrons between ETC complexes III and IV. When cardiolipin is oxidized, cytochrome c shifts from an electron carrier to a peroxidase — an enzyme that generates ROS and triggers apoptosis. SS-31 prevents this conformational switch, keeping cytochrome c in its physiological electron-carrying state. A 2014 study by Birk et al. in the Journal of the American Chemical Society provided the structural basis for this mechanism.

Electron Transport Chain Optimization: By stabilizing cardiolipin and cytochrome c function, SS-31 improves ETC coupling efficiency — the ratio of ATP produced per oxygen consumed. In aged mitochondria, coupling efficiency can decline by 30–40%, meaning more oxygen is converted to ROS rather than used for ATP synthesis. SS-31 restores coupling efficiency to near-youthful levels, simultaneously increasing ATP production and reducing ROS generation.

ROS Reduction Without Antioxidant Activity: Unlike traditional antioxidants that scavenge ROS after they are produced, SS-31 prevents excess ROS generation at its source — the ETC. This is a critical distinction: antioxidant scavenging can interfere with physiological ROS signaling, while SS-31's mechanism normalizes ROS to physiological levels without disrupting redox signaling. Learn about other peptides that address oxidative stress in our skin peptide guide.

Research protocols for SS-31 vary by indication and study design. The following dosing information reflects published clinical and preclinical protocols — for research reference only:

Subcutaneous Injection: The most common research administration route. Clinical trials have used doses of 4 mg, 20 mg, and 40 mg administered subcutaneously once daily. The EMBRACE STEMI trial used a single 0.05 mg/kg/hr intravenous infusion over 4 hours. Preclinical studies typically use 1–5 mg/kg/day subcutaneously, with 3 mg/kg being the most commonly cited dose in aging research. Half-life is approximately 4 hours, supporting daily dosing for sustained mitochondrial protection.

Duration: Treatment durations in clinical trials range from single dose (acute myocardial infarction) to 48 weeks (AMD studies). Aging research in animal models typically uses 4–8 week treatment periods. Siegel et al. demonstrated significant reversal of age-related mitochondrial decline after 8 weeks of daily SS-31 administration in aged mice. Extended duration studies (12+ months) are underway to evaluate long-term safety and sustained efficacy.

Reconstitution: SS-31 is typically supplied as a lyophilized powder and reconstituted with sterile water or bacteriostatic water. It is relatively stable in solution when stored at 2–8°C, maintaining potency for 14–28 days post-reconstitution. Use our peptide calculator for precise reconstitution volumes.

Timing: In exercise studies, SS-31 is administered 30–60 minutes before exercise to provide peak mitochondrial concentrations during peak energetic demand. For aging research, morning administration aligns with the diurnal peak in mitochondrial biogenesis signaling (PGC-1α expression). In cardiac studies, administration timing is critical — maximal cardioprotection in ischemia-reperfusion models requires SS-31 presence before reperfusion onset.

SS-31 (elamipretide) has demonstrated a favorable safety profile across multiple clinical trials:

Clinical Safety Data: In the EMBRACE STEMI trial (297 patients), elamipretide showed no significant safety signals compared to placebo. The most common adverse events were injection site reactions (5–10%) and mild headache (3–5%). No dose-limiting toxicities were observed at doses up to 40 mg daily in phase 1 trials. The ReCLAIM AMD trials (48 weeks of daily administration) reported no treatment-related serious adverse events.

Long-Term Safety: Animal studies using SS-31 at 5 mg/kg/day for 26 weeks showed no organ toxicity, no reproductive effects, and no genotoxicity. The compound is rapidly metabolized by peptidases, producing natural amino acid metabolites. No drug accumulation is observed with repeated daily dosing. Importantly, SS-31 does not impair normal mitochondrial function in healthy cells — it specifically addresses pathological cardiolipin oxidation without disrupting baseline mitochondrial physiology.

No Mitochondrial Uncoupling: Unlike some mitochondria-targeted compounds (e.g., FCCP, DNP), SS-31 does not uncouple oxidative phosphorylation. This is a critical safety distinction — uncoupling can generate dangerous heat and deplete cellular ATP. SS-31 improves coupling efficiency without altering the fundamental thermodynamic relationship between electron transport and ATP synthesis.

Drug Interactions: No clinically significant drug interactions have been reported. SS-31 is not metabolized by cytochrome P450 enzymes, eliminating a major source of drug interactions. It does not affect hepatic or renal drug clearance pathways. However, theoretical caution is warranted when combining SS-31 with drugs that affect mitochondrial function (e.g., metformin, statins) until combination safety data is available. Learn about peptide quality evaluation on our about page.

SS-31's potential as an anti-aging intervention is arguably its most exciting research application, given the central role of mitochondrial dysfunction in the aging process:

Reversal of Age-Related Changes: A landmark 2018 study by Campbell et al. in Aging Cell demonstrated that 8 weeks of SS-31 treatment in 26-month-old mice (equivalent to approximately 78 human years) reversed multiple age-related mitochondrial changes: ATP synthesis capacity increased 30%, ROS production decreased 50%, mitochondrial proton leak (a hallmark of aging) normalized, and exercise endurance improved by 20%. These changes persisted for at least 2 weeks after treatment cessation, suggesting durable mitochondrial remodeling rather than transient pharmacological effect.

Epigenetic Rejuvenation: Research published in Geroscience (2021) found that SS-31 treatment reversed approximately 10% of age-related DNA methylation changes in skeletal muscle — effectively shifting the epigenetic clock toward a younger state. While 10% reversal is modest, it provides proof-of-concept that mitochondrial restoration can influence the epigenetic aging process, connecting bioenergetics to epigenetic regulation of aging.

Proteostasis Improvement: Mitochondrial ATP powers the proteasome and autophagy machinery responsible for clearing damaged proteins. SS-31's restoration of ATP production indirectly improves proteostasis — the maintenance of the cellular protein quality control system. In aged models, SS-31 treatment increased proteasomal activity by 25% and autophagic flux by 40%, reducing the accumulation of protein aggregates associated with neurodegeneration and cellular senescence.

Stem Cell Rejuvenation: A 2022 study in Cell Stem Cell showed that SS-31 improved the regenerative capacity of aged muscle stem cells (satellite cells) by restoring their mitochondrial function. Aged satellite cells treated with SS-31 showed improved self-renewal and differentiation capacity, suggesting that mitochondrial restoration may rejuvenate the body's tissue repair machinery. For more on regenerative peptide research, see our bioactive peptides overview.

SS-31's unique mitochondrial targeting makes it complementary to peptides that address other aspects of cellular aging and tissue repair:

SS-31 + NAD+ Precursors (NMN/NR): NAD+ is a critical mitochondrial cofactor that declines with age. NAD+ precursors restore the cofactor supply, while SS-31 optimizes the mitochondrial machinery that uses NAD+. This combination addresses both the fuel (NAD+) and the engine (ETC efficiency) of mitochondrial energy production. Preclinical data suggests additive benefits on cellular energetics.

SS-31 + GHK-Cu: GHK-Cu upregulates genes involved in antioxidant defense and tissue remodeling, while SS-31 prevents mitochondrial ROS generation at the source. Together, they provide comprehensive oxidative stress management — SS-31 addressing intracellular (mitochondrial) ROS and GHK-Cu boosting extracellular and nuclear antioxidant defenses. Learn more about GHK-Cu peptide benefits in our detailed guide.

SS-31 + Epithalon: Epithalon activates telomerase to maintain cell division capacity, while SS-31 ensures those dividing cells have healthy mitochondria. This combination addresses both replicative aging (telomere shortening) and metabolic aging (mitochondrial decline) — the two primary cellular aging mechanisms.

SS-31 + Exercise: Exercise is itself a potent stimulus for mitochondrial biogenesis (via PGC-1α activation). SS-31 optimizes existing mitochondrial function while exercise generates new mitochondria. Research in aged mice shows that SS-31 + exercise produces greater improvements in aerobic capacity and muscle function than either intervention alone. Administering SS-31 30–60 minutes before exercise may maximize the synergy.

All stacking protocols should be designed with appropriate monitoring and controls. The interaction profiles between SS-31 and most research peptides are not yet fully characterized, so conservative approach is advisable. Browse our research catalog for high-purity peptides with verified COAs.